Abstract
Many side effects, both local or systemic, may result from topical steroid therapy, especially after long-lasting treatment with potent corticosteroids. Of particular importance are the depression of the hypothalamic pituitary adrenal axis and the local side-effects from topical application consisting mainly of skin atrophy. Advantan* is a new potent corticoid preparation that has been specially developed for the local treatment of corticoid-responsive dermatoses. The active ingredient is methylprednisolone aceponate (MPA). It should be noted that the local tolerance and the presence of systemic side-effects of MPA have been extensively investigated in healthy volunteers and have also been studied in patients. Animal studies (rats, rabbits) indicated that MPA can be classified as a corticoid with low atrophogenic potential. In a comparative study to evalute the atrophogenic potential of MPA in man, after long-term topical application in healthy volunteers under occlusive conditions (Duhring chamber), the three formulations with MPA (0.1% cream, ointment, fatty ointment) developed a significantly lower atrophogenic potential than a product containing clobetasol 17-propionate. Another conclusion was that the atrophogenic potential of MPA was comparable to that of betamethasone 17-valerate. This was confirmed by clinical trials. In 1145 patients suffering from various types of eczema who used MPA in cream and ointment, mild atrophy of the skin was observed in only one patient. Moreover, clinical signs of atrophy were present in only two out of a group of 673 patients (590 adult and 83 children) treated with MPA fatty ointment. In a group of 66 patients who used this same MPA fatty ointment during 3–4 months, no signs of skin atrophy were observed. Folliculitis or pustules occurred only in a small number of patients. Double-blind studies in 200 healthy volunteers with the three preparations of MPA, and their corticosteroid free bases revealed a low level of local adverse effects. Local adverse effects including the subjective complaints itching or burning as well as erythema, exsiccation, weeping, papules/ vesicles, fissures etc were reported in 5 to 6% of the patients, but led to a premature discontinuation of therapy in less than 1% of the treated patients. Systemic side effects have not been reported in patients treated to MPA. In 100 healthy adult volunteers treated intensively with 40 g of topical 0.1% MPA (three formulations) daily on 60% of the body surface under occlusion over 5 or 8 days, the cortisol levels always remained within the normal range and the circadian rhythm was maintained in all subjects. In patients receiving extensive treatment with MPA in psoriatic skin and in atopic dermatitis, the values for plasma cortisol slightly decreased but remained in the normal range while the circadian rhythm of the release of endogenous cortisol remained unchanged. These results suggest that MPA 0.1% cream, ointment and fatty ointment are safe. No serious or lasting adverse effects occurred. Infection of the skin will of course limit the application of MPA as with other topical glucocorticosteroids. The development of atrophy and telangiectasia will have to be carefully monitored. With regard to other adverse effects, 0.1% MPA compared well with the widely prescribed standard preparations of betamethasone 17-valerate. It can be concluded that because of the proven therapeutic efficacy, the excellent tolerance and the low systemic activity the risk/benefit ratio is very favourable for MPA.